60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns Neutral Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report released on Wednesday morning,Benzinga reports.

60 Degrees Pharmaceuticals Stock Down 14.5 %

SXTP stock opened at $1.41 on Wednesday. 60 Degrees Pharmaceuticals has a fifty-two week low of $0.70 and a fifty-two week high of $18.36. The firm’s 50-day simple moving average is $1.05 and its 200 day simple moving average is $0.85. The stock has a market cap of $3.24 million, a PE ratio of -0.14 and a beta of 5.36.

Insider Buying and Selling at 60 Degrees Pharmaceuticals

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow acquired 35,823 shares of the stock in a transaction dated Monday, December 9th. The shares were bought at an average price of $1.27 per share, with a total value of $45,495.21. Following the purchase, the chief executive officer now directly owns 94,580 shares of the company’s stock, valued at approximately $120,116.60. This trade represents a 60.97 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have purchased 59,372 shares of company stock valued at $70,410. Company insiders own 10.27% of the company’s stock.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.